Canadian man diagnosed with Guillain-Barré Syndrome following 1st dose of ChAdOx1-S vaccine unable to get an exemption from 2nd dose

A ~30-40-year-old male was given a dose of the AstraZeneca vaccine in April 2021. Within days, he started to have excruciating back pain. Then came the tingles on the side of his face — and then, paralysis.

He was diagnosed with Guillain-Barré Syndrome (GBS), a rare condition that affects the nervous system. It can cause paralysis, muscle weakness, and even death. 

This condition has been linked to COVID-19 vaccination with all types of vaccines and wide range of ages (eg, Pfizer: 67-year-old male, Pfizer: 14-year old male,  Astrazeneca: 66-year old male)

Review of 9 cases that occurred in persons with a mean age of 57.8 (range 20–86) years,  56.4% male, showed that most of the reported case-patients received ChAdOx1-S (25/39), followed by BNT162b2 (12/39) (Pfizer-BioNTech), Ad26.COV2.S (1/39) (Johnson & Johnson), and CoronaVac (1/39). The GBS rate after COVID-19 vaccination ranged from 1.8 to 53.2 cases/1 million doses. There were two deaths associated with Ad26.COV2.S-induced GBS in South Africa. 

The Canadian man spent two months in the hospital, and the condition has left him unable to work as he tries to access slow-moving government support for vaccine injury.

He's been unable to get an exemption from receiving the 2nd dose of COVID-19 vaccine, with health officers saying they can't prove his GBS was caused by the AstraZeneca shot — and advising him to get a second dose of a different COVID-19 vaccine. 


B.C. man who had rare, extreme reaction to COVID-19 vaccine still waiting for exemption, government support | CBC News


Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

COVID in May

Navigating the Tripledemic: JN.1, RSV, and Flu Update